Once administered to mice, rPCN interacts with TLRs, induces IL-12 production, thereby driving immunity to the Th1 axis, with a balanced bias due to concomitant production of IL-10, and modification of the course of experimental PCM. This evidence concerns the gene IL10 and paracoccidioidomycosis.